3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
10
Recurrence
7
Lymphoma
5
Lymphoma, T-Cell
4
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large-Cell, Anaplastic
3
Hodgkin Disease
3
Waldenstrom Macroglobulinemia
2
Unspecified Adult Solid Tumor, Protocol Specific
2
Sezary Syndrome
2
Neoplasm Metastasis
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Immunoblastic Lymphadenopathy
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Smoking
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Interventions
Rituximab
193
Cyclophosphamide
177
fludarabine phosphate
151
Peripheral Blood Stem Cell Transplantation
89
fludarabine
77
Mycophenolic Acid
70
Filgrastim
63
Whole-Body Irradiation
59
Tacrolimus
55
Lenalidomide
54
Cyclosporine
54
ibrutinib
53
Bendamustine Hydrochloride
50
Busulfan
49
Melphalan
45
Radiotherapy
42
Etoposide
42
Alemtuzumab
42
Antilymphocyte Serum
40
ofatumumab
35
obinutuzumab
33
Methotrexate
33
venetoclax
27
Cytarabine
25
sargramostim
23
Granulocyte Colony-Stimulating Factor
22
Dexamethasone
21
Methylprednisolone
19
Bortezomib
19
Chlorambucil
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT01947140
2022-11-23
PDX+Romi
Columbia University
Phase 1/2
Completed
57 enrolled